Medtronic Acquires SPR Therapeutics for $650M: Expanding Neuromodulation Into Non-Opioid Chronic Pain Management

The Deal at a Glance

On May 20, 2026, Medtronic plc (NYSE: MDT) announced its intent to acquire SPR Therapeutics, a privately held medical device company based in Cleveland, Ohio, for $650 million in an upfront cash payment. The deal adds SPR's FDA-cleared SPRINT peripheral nerve stimulation (PNS) system to Medtronic's Neuromodulation portfolio, giving the company a minimally invasive, non-permanent option for chronic pain management that fills an acknowledged gap in its pain therapy continuum.

The transaction is subject to customary closing conditions and regulatory approvals and is expected to close in the first half of Medtronic's fiscal year 2027, which began April 25, 2026. Medtronic expects the acquisition to be minimally dilutive to adjusted earnings per share in FY2027 and neutral to accretive thereafter.

The Players

Medtronic plc

Medtronic is the world's largest medical device company, headquartered in Galway, Ireland, with its operational headquarters in Minneapolis, Minnesota. The company operates across four major business segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes (with the diabetes business being separated into the independently traded MiniMed in early 2026).

Within the Neuroscience portfolio, Medtronic's Neuromodulation business has been a cornerstone of the company for over 50 years. The division develops implantable devices that deliver targeted electrical stimulation to treat chronic pain, movement disorders, and other neurological conditions. Key products include:

• Inceptiv closed-loop spinal cord stimulation (SCS) system — FDA cleared in April 2024, this next-generation SCS device uses closed-loop sensing to automatically adjust stimulation in real time based on the patient's neural response
• SenSight Directional DBS Lead System — a deep brain stimulation platform for Parkinson's disease, essential tremor, dystonia, and epilepsy
• A broad legacy portfolio of spinal cord stimulation and deep brain stimulation systems accumulated over five decades

Notably, this acquisition coincides with a leadership transition in Medtronic's Neuromodulation business. Brett Wall, the longtime president of Medtronic's Neuroscience Portfolio, is departing. Domenico De Paolis is serving as interim president of the Neuromodulation unit, overseeing the integration of SPR Therapeutics into the broader pain therapy strategy.

SPR Therapeutics

SPR Therapeutics is a privately held medical device company based in Cleveland, Ohio, focused on developing non-opioid, minimally invasive pain therapies using peripheral nerve stimulation. The company was founded and led by CEO Maria E. Bennett, who has been a prominent advocate for PNS as an earlier-stage intervention in the pain management continuum — positioned before more invasive surgical options like spinal cord stimulation.

SPR's flagship product is the SPRINT PNS System, an FDA-cleared temporary peripheral nerve stimulation device that has treated thousands of patients with chronic pain. The company has built a substantial body of clinical evidence supporting its technology, with studies encompassing over 6,100 patients.

The SPRINT PNS System

Device Design and Mechanism of Action

The SPRINT PNS System represents a fundamentally different approach to neuromodulation for chronic pain. Unlike traditional spinal cord stimulation or deep brain stimulation, which require permanently implanted pulse generators and surgical leads, the SPRINT system delivers temporary, percutaneous peripheral nerve stimulation over a defined 60-day treatment period.

The system consists of three main components:

1. MicroLead — A hair-thin, fine wire that is percutaneously inserted through the skin and positioned near the targeted peripheral nerve under ultrasound or fluoroscopic guidance. The lead is small enough to be placed in an outpatient setting without an operating room.

2. Wearable external pulse generator — A small, wearable device that connects to the MicroLead and delivers gentle electrical pulses to the targeted nerve. Because the pulse generator is external, no surgical pocket creation is required.

3. Lead withdrawal system — After the 60-day treatment period, the MicroLead is simply withdrawn through the skin in a non-surgical procedure, leaving no permanent hardware in the body.

Mechanism of Action

The SPRINT system works by delivering gentle electrical stimulation to a targeted peripheral nerve. Peripheral nerve stimulation is believed to modulate pain signals through several mechanisms:

• Gate control theory — Electrical activation of large-diameter afferent nerve fibers can inhibit the transmission of pain signals through smaller-diameter nociceptive fibers at the level of the spinal cord dorsal horn
• Descending pain inhibition — Peripheral nerve stimulation may activate descending inhibitory pathways from the brainstem that suppress pain processing
• Neuromodulatory plasticity — Sustained electrical stimulation over the 60-day treatment period may induce neuroplastic changes that persist after the stimulation ends, providing lasting pain relief even after the lead is removed

Clinical Workflow

The SPRINT PNS System is designed to integrate into existing clinical workflows, which is a key selling point for adoption in pain clinics, physical medicine and rehabilitation practices, and orthopedic settings:

1. Patient evaluation — The physician identifies a patient with chronic pain that has not responded adequately to conservative treatments (physical therapy, medications, injections). A target peripheral nerve is selected based on the pain distribution.

2. Lead placement — In an outpatient setting, the physician uses ultrasound or fluoroscopic guidance to percutaneously insert the hair-thin MicroLead near the targeted nerve. No incision, general anesthesia, or operating room is required.

3. Stimulation programming — The wearable external pulse generator is connected and programmed to deliver gentle electrical stimulation at the appropriate amplitude, frequency, and pulse width for the individual patient.

4. 60-day treatment period — The patient wears the external pulse generator and receives continuous or cycled stimulation for up to 60 days. During this period, stimulation parameters can be adjusted non-invasively.

5. Lead withdrawal — After 60 days, the MicroLead is withdrawn through the skin in a brief, non-surgical procedure. No permanent hardware remains in the body.

Key Differentiators

The SPRINT PNS System has several important distinctions compared to traditional neuromodulation approaches:

The temporary, non-permanent nature of the SPRINT system is its defining characteristic. It allows physicians to offer a neuromodulation intervention without the clinical and psychological commitment of a permanent implant — and patients who experience meaningful pain relief can subsequently be considered for more permanent neuromodulation options if needed.

Clinical Evidence

SPR Therapeutics has built one of the largest clinical evidence bases in peripheral nerve stimulation. A study encompassing over 6,100 patients demonstrated that more than 71% of patients experienced significant pain relief and/or improvement in quality of life following treatment with the SPRINT PNS System.

This level of clinical evidence is notable for several reasons:

1. Large sample size — Over 6,100 patients represents a substantial real-world evidence base, far larger than most device studies that rely on randomized controlled trials of a few hundred patients.

2. Clinically meaningful outcomes — The 71%+ responder rate for significant pain relief and quality of life improvement exceeds commonly accepted thresholds for clinical significance in pain studies, where a 30% reduction in pain intensity is typically considered meaningful.

3. Durability signal — Importantly, patients have reported sustained pain relief even after the 60-day stimulation period ends and the lead is removed. This suggests that temporary peripheral nerve stimulation may induce lasting neuromodulatory changes, rather than simply masking pain during the treatment window.

4. Broad applicability — The SPRINT system has been studied across multiple pain conditions and anatomical targets, supporting its use in diverse chronic pain populations.

The strength of this evidence base was undoubtedly a factor in Medtronic's decision to acquire SPR Therapeutics at a $650 million valuation. The clinical data de-risks the acquisition by demonstrating that the technology delivers meaningful outcomes across a large patient population, not just in controlled trial settings.

Medtronic's Pain Therapy Continuum

The Strategic Gap

Medtronic's acquisition of SPR Therapeutics fills an acknowledged gap in its pain therapy lineup. Before this deal, Medtronic's neuromodulation portfolio for chronic pain was anchored at the more invasive end of the treatment spectrum:

• Spinal cord stimulation (SCS) — Requires a permanent implanted pulse generator surgically placed in the abdomen or buttock, with leads positioned in the epidural space. Medtronic's Inceptiv system, FDA cleared in April 2024, represents the latest generation of SCS technology with closed-loop sensing.

• Deep brain stimulation (DBS) — The most invasive neuromodulation approach, requiring neurosurgical implantation of leads deep within the brain. Medtronic's SenSight Directional DBS system is used primarily for movement disorders but also has applications in certain pain syndromes.

What was missing from Medtronic's portfolio was a minimally invasive option that could be offered earlier in the treatment continuum — before a patient is ready for or appropriate for a permanent SCS or DBS implant. The SPRINT PNS System fills exactly that gap.

The Complete Pain Therapy Continuum

With the addition of the SPRINT system, Medtronic can now offer what it describes as the industry's broadest pain therapy portfolio, spanning the full continuum from least to most invasive:

This continuum approach is strategically powerful for several reasons:

1. Capture patients earlier — Many chronic pain patients are reluctant to undergo permanent implant surgery. The temporary SPRINT system allows Medtronic to enter the treatment pathway at an earlier stage, establishing a relationship with patients and referring physicians before they progress to more invasive options.

2. Natural progression pathway — Patients who respond well to temporary PNS but whose pain returns after lead removal can be seamlessly transitioned to SCS or DBS within Medtronic's portfolio. This creates a "pipeline" effect where the SPRINT system serves as both a therapeutic option and a referral funnel for Medtronic's permanent implant business.

3. Broader referring physician base — The SPRINT system's outpatient, non-surgical placement workflow means it can be adopted by pain medicine physicians, physiatrists, and orthopedic surgeons who do not perform surgical implant procedures. This expands Medtronic's reach beyond the neurosurgeons and pain specialists who implant SCS and DBS systems.

4. Payer negotiation leverage — A complete continuum allows Medtronic to negotiate with payers from a position of strength, offering a step-therapy approach that begins with the lowest-cost, least-invasive option and escalates only as clinically necessary.

The Competitive Landscape

The PNS Market Heats Up: Boston Scientific and Nalu Medical

Medtronic is not the only major neuromodulation company making a play in peripheral nerve stimulation. In a striking parallel, Boston Scientific also executed a PNS-focused acquisition, agreeing to acquire Nalu Medical for approximately $600 million.

The near-simultaneous PNS acquisitions by the two largest neuromodulation companies signal a competitive recognition that peripheral nerve stimulation represents a significant growth opportunity that neither company could afford to cede to the other.

The different technical approaches are worth noting. SPR's SPRINT system is temporary, designed to be used for 60 days and then removed, leaving no hardware behind. Nalu's system, by contrast, uses a miniaturized permanent implant. Both approaches have merit, and the market may ultimately reward both depending on physician preference and patient characteristics.

Other PNS Players

Beyond Medtronic and Boston Scientific, the PNS market includes several other companies:

• Nevro — Known for its Senza SCS system using HF10 therapy, Nevro has also explored PNS applications
• Abbott — Through its St. Jude Medical neuromodulation heritage, Abbott has PNS capabilities alongside its SCS portfolio
• Bioness — Develops PNS systems for pain and functional restoration
• SPR Therapeutics competitors in temporary PNS — Several smaller companies are developing temporary PNS systems, though SPR's clinical evidence base of 6,100+ patients gives it a significant lead

The Neuromodulation Market

Market Size and Growth Drivers

The neuromodulation device market is experiencing robust growth, driven by several converging factors:

1. Chronic pain epidemic — Chronic pain affects nearly 50 million US adults, making it one of the most prevalent health conditions in the country. The economic burden of chronic pain, including healthcare costs and lost productivity, is estimated at hundreds of billions of dollars annually.

2. Opioid crisis driving non-pharmacological alternatives — The ongoing opioid crisis has created urgency around developing and adopting non-pharmacological pain treatments. Payer policies, regulatory initiatives, and clinical guidelines increasingly favor non-opioid approaches, creating a favorable environment for neuromodulation therapies.

3. Aging population — As the US population ages, the prevalence of chronic pain conditions (osteoarthritis, spinal stenosis, neuropathy, complex regional pain syndrome) increases, expanding the addressable patient population.

4. Technology advancement — Closed-loop sensing, directional leads, miniaturized implants, and temporary percutaneous systems are expanding the clinical utility and patient acceptance of neuromodulation.

5. Expanding indications — Beyond chronic pain, neuromodulation is being studied for conditions including depression, obesity, heart failure, and urinary incontinence, potentially dramatically expanding the market.

PNS as an Earlier-Stage Intervention

Peripheral nerve stimulation occupies a distinct and strategically important position in the pain management care continuum. Compared to spinal cord stimulation, PNS:

• Targets specific peripheral nerves rather than the spinal cord dorsal columns
• Is less invasive to place and does not require epidural access
• Can be offered earlier in the treatment algorithm, often before patients have exhausted all pharmacological options
• Has a more favorable risk profile due to the superficial location of peripheral nerves
• Can serve as a "bridge" therapy — providing relief while more definitive treatments are planned or healing occurs

The "step therapy" model that PNS enables — progressing from conservative management to temporary PNS to permanent SCS or DBS — aligns with payer preferences for evidence-based escalation of care and value-based reimbursement models.

Medtronic's 2025-2026 Acquisition Strategy

The Broader Context

The SPR Therapeutics acquisition must be understood within the context of Medtronic's broader M&A strategy in 2025-2026, which has been characterized by a series of targeted tuck-in acquisitions in high-growth areas.

After spinning off its Diabetes business as MiniMed (Nasdaq: MMED) in early 2026, CEO Geoff Martha articulated a strategy of "going on the offense" — using freed-up capital and management bandwidth to pursue focused acquisitions that strengthen Medtronic's position in its highest-growth, highest-margin franchises.

2026 Acquisition Timeline

In the span of approximately three months (February–May 2026), Medtronic committed nearly $1.8 billion to three acquisitions that collectively strengthen its cardiovascular and neuroscience franchises — the two business segments identified as the company's highest priority growth engines.

Strategic Pattern

Several patterns emerge from this acquisition strategy:

1. Tuck-in, not transformative — All three deals are tuck-in acquisitions that add specific technological capabilities to existing business units, rather than transforming Medtronic's business model or entering entirely new markets.

2. Clinical evidence matters — Each target brought substantial clinical evidence. CathWorks had multiple published studies validating its FFRangio system. Scientia Vascular had physician testimonials and growing clinical adoption. SPR Therapeutics had data from over 6,100 patients. This evidence de-risks the acquisitions and accelerates the path to commercial return.

3. Complementary, not overlapping — Each acquisition fills a specific gap in Medtronic's portfolio. CathWorks adds non-invasive physiology assessment to complement Medtronic's coronary intervention tools. Scientia adds access devices to complement Medtronic's neurovascular therapeutic tools. SPR adds temporary PNS to complement Medtronic's permanent neuromodulation implants.

4. Pricing discipline — Deal values range from $550 million to $650 million, suggesting Medtronic is adhering to valuation discipline rather than overpaying for strategic positioning. The consistent price range also suggests these targets are of similar maturity and scale — established companies with FDA-cleared products and meaningful commercial traction, rather than early-stage startups.

What This Means for the Industry

For Neuromodulation Companies

1. The pain therapy continuum is the new competitive battlefield. Medtronic's acquisition gives it a complete continuum from temporary PNS through permanent SCS to DBS. Competitors who can only offer one segment of this continuum will find it increasingly difficult to compete for hospital formulary positions and integrated health system contracts.

2. PNS is now a must-have, not a nice-to-have. The fact that both Medtronic and Boston Scientific made major PNS acquisitions within a short timeframe signals that peripheral nerve stimulation has crossed the threshold from niche therapy to mainstream offering. Any neuromodulation company without a PNS strategy risks being left behind.

3. Temporary versus permanent PNS will be a key competitive dimension. Medtronic's temporary 60-day approach (via SPR) and Boston Scientific's permanent miniaturized implant approach (via Nalu) represent different philosophies. The market will ultimately determine which approach gains broader adoption, and physician and patient preference may vary by indication and practice setting.

For Pain Management Physicians

1. Expanded toolbox. The availability of a temporary, non-permanent PNS option gives pain physicians a new tool for patients who have failed conservative treatments but are not yet ready for permanent implants. This fills a therapeutic gap that has existed for years.

2. Lower threshold for neuromodulation referral. Because the SPRINT system is placed in an outpatient setting without an operating room, the threshold for referring patients for neuromodulation evaluation may decrease, expanding the addressable patient population.

3. Step-therapy alignment with payers. The ability to offer a graduated approach — temporary PNS before permanent SCS — aligns with payer step-therapy requirements and may improve authorization rates for neuromodulation interventions.

For Startups and Investors

1. PNS is a validated acquisition target. The $600-650 million valuations for SPR Therapeutics and Nalu Medical demonstrate that PNS companies can achieve significant exits, validating the investment thesis for PNS-focused startups.

2. Clinical evidence at scale commands premium valuations. SPR's database of 6,100+ patients was a key differentiator that justified its acquisition price. Startups building large real-world evidence registries alongside traditional clinical trials are better positioned for attractive exits.

3. The tuck-in acquisition window remains open. Medtronic's 2026 acquisition spree suggests that large-cap medtech companies are actively seeking tuck-in targets with FDA-cleared products and commercial traction. Companies in the $500 million to $1 billion valuation range with complementary technologies are prime candidates.

For Patients

1. More non-opioid options. The expansion of neuromodulation into earlier stages of the pain management pathway gives patients more non-pharmacological options before escalating to permanent implants or long-term opioid therapy.

2. Less invasive first step. A temporary 60-day PNS trial that leaves no hardware behind represents a lower-risk, lower-commitment entry point into neuromodulation therapy, potentially reducing patient anxiety about proceeding with treatment.

3. Improved access through competition. As both Medtronic and Boston Scientific invest heavily in PNS, competition will drive innovation, improve reimbursement coverage, and expand the network of physicians trained to place PNS systems.

Key Takeaways

• Medtronic announced a $650 million acquisition of SPR Therapeutics on May 20, 2026, adding the FDA-cleared SPRINT temporary peripheral nerve stimulation system to its neuromodulation portfolio
• The SPRINT PNS System delivers 60 days of percutaneous peripheral nerve stimulation through a hair-thin MicroLead connected to a wearable external pulse generator, with the lead withdrawn after treatment — no permanent implant required
• Clinical evidence from over 6,100 patients shows more than 71% experienced significant pain relief and/or quality of life improvement
• The deal fills a strategic gap in Medtronic's pain therapy continuum, enabling a step-care model from temporary PNS to permanent spinal cord stimulation (Inceptiv) to deep brain stimulation (SenSight)
• Boston Scientific's parallel $600 million acquisition of Nalu Medical confirms that PNS has become a strategic priority for major neuromodulation companies
• This is Medtronic's third major tuck-in acquisition in 2026, following Scientia Vascular ($550 million) and CathWorks ($585 million), totaling nearly $1.8 billion committed to strengthening cardiovascular and neuroscience franchises
• The acquisition is expected to close in the first half of Medtronic FY2027 (April-October 2026), pending customary closing conditions and regulatory approvals
• Chronic pain affects nearly 50 million US adults, and the opioid crisis continues to drive demand for non-pharmacological alternatives — positioning neuromodulation for sustained growth